LXEO
Q4 2026 EPS Estimate
$-0.32
Dec 14, 2026 · Reports before open
FY2029E EPS$0.59
FY2030E EPS$2.71

Analyst Sentiment

Wall St. Consensus
Buy
5 analysts·Limited coverage
75
Score
5 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
5100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$10.00
+91.4%
Consensus
$20.00
+282.8%
Bull
$30.00
+474.2%
12-Month Target Range5 analysts
$10.00$20.00$30.00
Current $5.22Consensus
Current Price
$5.22
Upside to Consensus
$14.78

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev+1020.15%
EPS
FY2029
Rev+206.10%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$7M$77M$236M$481M
Low$7M$77M$236M$481M
High$7M$77M$236M$481M
EBITDA Avg$1M$15M$47M$96M
Low$1M$15M$47M$96M
High$1M$15M$47M$96M
EBIT Avg$1M$15M$47M$96M
Low$1M$15M$47M$96M
High$1M$15M$47M$96M
Net Income Avg$-64M$-65M$-34M$32M$145M
Low$-75M$-83M$-83M$32M$145M
High$-52M$-47M$14M$32M$145M
EPS Avg$-1.16$-1.28$-0.76$0.59$2.71
Low$-1.41$-1.56$-1.54$0.59$2.71
High$-0.97$-0.88$0.26$0.59$2.71
Analysts (Rev / EPS) / 76 / 76 / 54 / 13 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$5M
Low$5M
High$5M
EBITDA Avg$933,333
Low$933,333
High$933,333
EBIT Avg$933,333
Low$933,333
High$933,333
Net Income Avg$-26M$-28M$-28M$-28M$-27M$-26M
Low$-32M$-30M$-28M$-28M$-27M$-26M
High$-21M$-27M$-28M$-28M$-27M$-26M
EPS Avg$-0.31$-0.32$-0.33$-0.33$-0.31$-0.30
Low$-0.37$-0.35$-0.33$-0.33$-0.31$-0.30
High$-0.25$-0.31$-0.33$-0.33$-0.31$-0.30
Analysts (Rev / EPS) / 5 / 7 / 2 / 2 / 21 / 5

Earnings Surprises

Recent Analyst Actions

Jan 13, 2026H.C. Wainwright
Lexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright
Target:$10.00
+23.2%from $8.12
Dec 17, 2025Raymond James
Lexeo Therapeutics initiated with a Strong Buy at Raymond James
Target:$25.00
+174.4%from $9.11
Dec 10, 2025Oppenheimer
Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO)
Target:$20.00
+110.4%from $9.51
Nov 20, 2025Cantor Fitzgerald
Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Target:$19.00
+109.0%from $9.09
Oct 21, 2025H.C. Wainwright
Lexeo Therapeutics price target lowered to $13 from $15 at H.C. Wainwright
Target:$13.00
+41.0%from $9.22
Oct 15, 2025Guggenheim
Lexeo Therapeutics initiated with a Buy at Guggenheim
Target:$30.00
+252.9%from $8.50
Oct 7, 2025Chardan Capital
Lexeo Therapeutics price target raised to $17 from $15 at Chardan
Target:$17.00
+106.1%from $8.25
Oct 7, 2025H.C. Wainwright
Lexeo Therapeutics price target raised to $15 from $9 at H.C. Wainwright
Target:$15.00
+81.8%from $8.25
Oct 7, 2025Leerink Partners
Lexeo Therapeutics price target raised to $20 from $9 at Leerink
Target:$20.00
+142.4%from $8.25
Jun 12, 2024Robert W. Baird
Lexeo Therapeutics initiated with an Outperform at Baird
Target:$28.00
+53.9%from $18.19
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.